Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lipoic acid for CIAKI prevention in type 2 diabetes
NCT01978405Phase 4Unknown
- Start
- Nov 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alpha-lipoic acid in contrast-induced acute kidney injury (CI-AKI). Primary endpoint: Contrast-induced acute kidney injury at 6 months. Status: unknown.
02
Drugs
alpha-lipoic acid
03
Conditions
contrast-induced acute kidney injury (CI-AKI)
Beyond the preview
Go deeper on NCT01978405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01978405.